A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions.
A versatile expression vector is described for the rapid construction and evaluation of bispecific scFvs and scFv-based fusion proteins. An important feature of this vector is the presence of two multiple cloning sites (MCS) separated by an in frame linker sequence. The first MCS was specifically designed to contain unique SfiI and NotI restriction enzyme sites that can be used for directional and in frame insertion of scFvs (or potentially any molecule) selected from established phage-display systems. Using this new vector, a functional bs-(scFv)(2) (2C11-MOC31) was constructed for retargeted T-cell cytotoxicity towards EGP2 positive tumor cells. The vector was also used for grafting of a number of promising biological effector principles onto scFv MOC31, including the prodrug converting enzyme cytosine deaminase, the anti-angiogenic factor angiostatin, and the thrombogenic molecule tissue factor. We aimed at producing biologically active fusion proteins by directing them through the endoplasmic reticulum-based protein folding machinery of eukaryotic cells (COS-7) using a kappa light chain leader, thereby taking advantage of the associated quality control mechanisms that allow only fully folded and processed fusion proteins to be secreted into the medium. Supernatants derived from fusion protein transfected COS-7 cells, which were transiently transfected at low transfection rates, were directly assayed for the biological and/or targeting activity of the excreted fusion proteins without any prior purification steps. This procedure might help to identify those fusion proteins that have favourable characteristics like stability and biological activity in the presence of serum and at low protein concentrations. Targeted delivery of all effector principles was subsequently assessed in an in vitro model system. The method we devised is both rapid and versatile and can be useful to construct and identify series of new chimeric proteins with enhanced therapeutic potential in human cancer therapy.
Helfrich
W
W
Groningen University Institute for Drug Exploration (GUIDE) at the University Hospital Groningen, Department of Pathology and Laboratory Medicine, Medical Biology Branch, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. w.helfrich@med.rug.nl
Haisma
H J
HJ
Magdolen
V
V
Luther
T
T
Bom
V J
VJ
Westra
J
J
van der Hoeven
R
R
Kroesen
B J
BJ
Molema
G
G
de Leij
L
L
D043168:Angiostatins; D000818:Animals; D001483:Base Sequence; D019556:COS Cells; D043525:Cytosine Deaminase; D003602:Cytotoxicity, Immunologic; D017931:DNA Primers / Q000235:genetics; D015870:Gene Expression; D005822:Genetic Vectors; D006801:Humans; D007128:Immunoglobulin Fragments / Q000096:biosynthesis / Q000235:genetics* / Q000302:isolation & purification*; D066298:In Vitro Techniques; D051379:Mice; D008969:Molecular Sequence Data; D009700:Nucleoside Deaminases / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D010446:Peptide Fragments / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D010957:Plasmids / Q000235:genetics; D010958:Plasminogen / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D017510:Protein Folding; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D013925:Thromboplastin / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D014162:Transfection; D014407:Tumor Cells, Cultured
D017931:DNA Primers; D007128:Immunoglobulin Fragments; D010446:Peptide Fragments; D011993:Recombinant Fusion Proteins; C055966:immunoglobulin Fv; D043168:Angiostatins; D010958:Plasminogen; D013925:Thromboplastin; D009700:Nucleoside Deaminases; D043525:Cytosine Deaminase